Publicaciones (127) Publicaciones en las que ha participado algún/a investigador/a

2024

  1. CEA-CD3 bispecific antibody cibisatamab with or without atezolizumab in patients with CEA-positive solid tumours: results of two multi-institutional Phase 1 trials

    Nature Communications, Vol. 15, Núm. 1

  2. Case–control study assessing the impact of COVID19 in advanced kidney cancer patients treated with antiangiogenics or immunotherapy: the COVID-REN study

    Clinical and Translational Oncology, Vol. 26, Núm. 3, pp. 732-738

  3. Cytotoxicity as a form of immunogenic cell death leading to efficient tumor antigen cross-priming

    Immunological Reviews, Vol. 321, Núm. 1, pp. 143-151

  4. Dendritic Cells in Cancer Immunology and Immunotherapy

    Cancers, Vol. 16, Núm. 5

  5. Efficacy of LCMV-based cancer immunotherapies is unleashed by intratumoral injections of polyI:C

    Journal for ImmunoTherapy of Cancer, Vol. 12, Núm. 4

  6. Final results of urelumab, an anti-CD137 agonist monoclonal antibody, in combination with cetuximab or nivolumab in patients with advanced solid tumors

    Journal for ImmunoTherapy of Cancer, Vol. 12, Núm. 3

  7. Intratumoral NK cell delivery combined with neutralization of the NKG2A pathway as treatment for solid cancer

    Genes and Immunity

  8. Nivolumab in sorafenib-naive and sorafenib-experienced patients with advanced hepatocellular carcinoma: 5-year follow-up from CheckMate 040

    Annals of Oncology, Vol. 35, Núm. 4, pp. 381-391

  9. Nivolumab plus ipilimumab combination therapy in patients with advanced hepatocellular carcinoma previously treated with sorafenib: 5-year results from CheckMate 040

    Annals of Oncology, Vol. 35, Núm. 6, pp. 537-548

  10. Obinutuzumab Pretreatment as a Novel Approach to Mitigate Formation of Anti-Drug Antibodies Against Cergutuzumab Amunaleukin in Patients with Solid Tumors

    Clinical Cancer Research, Vol. 30, Núm. 8, pp. 1630-1641

  11. Sequential immunotherapy and targeted therapy for metastatic BRAF V600 mutated melanoma: 4-year survival and biomarkers evaluation from the phase II SECOMBIT trial

    Nature Communications, Vol. 15, Núm. 1

  12. Society for Immunotherapy of Cancer (SITC) recommendations on intratumoral immunotherapy clinical trials (IICT): from premalignant to metastatic disease

    Journal for ImmunoTherapy of Cancer, Vol. 12, Núm. 4

  13. Spatially resolved tissue imaging to analyze the tumor immune microenvironment: beyond cell-type densities

    Journal for immunotherapy of cancer, Vol. 12, Núm. 5

  14. The liver as a cytokine factory working on mRNA blueprints for cancer immunotherapy

    Cancer Cell

  15. Tumor slice culture system for ex vivo immunotherapy studies

    Methods in Cell Biology (Academic Press Inc.)

  16. Whole exome sequencing and machine learning germline analysis of individuals presenting with extreme phenotypes of high and low risk of developing tobacco-associated lung adenocarcinoma

    eBioMedicine, Vol. 102

2023

  1. A first-in-human study of the fibroblast activation protein-targeted, 4-1BB agonist RO7122290 in patients with advanced solid tumors

    Science translational medicine, Vol. 15, Núm. 695, pp. eabp9229

  2. Author Correction: Long-term retention of antigens in germinal centers is controlled by the spatial organization of the follicular dendritic cell network (Nature Immunology, (2023), 24, 8, (1281-1294), 10.1038/s41590-023-01559-1)

    Nature Immunology

  3. CD137 (4-1BB) requires physically associated cIAPs for signal transduction and antitumor effects

    Science advances, Vol. 9, Núm. 33, pp. eadf6692

  4. CD137 (4-1BB)-Based Cancer Immunotherapy on Its 25th Anniversary

    Cancer discovery, Vol. 13, Núm. 3, pp. 552-569